التفاصيل البيبلوغرافية
| العنوان: |
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. |
| المؤلفون: |
Hsu, Shih-Jer, Enkhzaya, Sukhee, Lin, You-Yu, Tseng, Tai-Chung, Khosbayar, Tulgaa, Tsai, Cheng-Hsueh, Wang, Tzu-San, Enkhtuya, Damba, Ivshinkhorol, Dogsom, Naranzul, Nyamsuren, Jargalsaikhan, Badarch, Amarsanaa, Jazag, Baatarkhuu, Oidov, Kao, Jia-Horng |
| المصدر: |
Journal of the Formosan Medical Association; Mar2020, Vol. 119 Issue 3, p712-719, 8p |
| مصطلحات موضوعية: |
CHRONIC hepatitis C, ALANINE aminotransferase, HEPATITIS C virus, TREATMENT effectiveness, NUCLEOTIDE sequencing |
| مصطلحات جغرافية: |
MONGOLIA |
| مستخلص: |
Background: Mongolia has the highest prevalence of hepatitis C virus (HCV) infection worldwide. Ledipasvir/sofosbuvir (LDV/SOF) was introduced to Mongolia since 2016 for HCV eradication. It has been reported that HCV resistance-associated substitutions (RASs) would affect the effectiveness of LDV/SOF in western chronic hepatitis C (CHC) patients. We thus investigated the effectiveness of LDV/SOF and the impact of RAS on the treatment outcome in Mongolian CHC patients.Methods: Patients with genotype (GT) 1b HCV infection were prospectively enrolled in Mongolia and treated with LDV/SOF for 12 weeks. The proportion of pre-treatment NS5A Y93H RAS in viral quasispecies was measured with next-generation sequencing. The endpoint of LDV/SOF effectiveness was sustained virological response at post-treatment week 12 (SVR12).Results: A total of 94 CHC patients were evaluated. The baseline Y93H proportion was <1% in 74 patients, 1-15% in 7, 15-50% in 2, and ≥50% in 11. All patients completed 12-week LDV/SOF treatment and the SVR rate was 90.4%. The rate of failure to achieve SVR12 for patients with Y93H < 1%, 1-15%, and ≥15% were 0%, 14.3%, and 61.5%, respectively (p for trend = 0.001). In univariable analysis, older age, baseline alanine transaminase level <40 U/mL, and a higher proportion of Y93H were associated with treatment failure. In multivariable analysis, only a higher proportion of Y93H was associated with treatment failure (p = 0.022).Conclusion: LDV/SOF therapy achieves a high SVR rate in Mongolian CHC GT1b patients without baseline Y93H RAS. A higher proportion of Y93H may severely undermine the effectiveness of LDV/SOF. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of the Formosan Medical Association is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder